90 related articles for article (PubMed ID: 1597651)
1. Induction of immune rejection of tumors by protein A in mice bearing transplantable solid tissue Dalton's lymphoma tumors.
Dwivedi PD; Verma AS; Ray PK
Immunopharmacol Immunotoxicol; 1992; 14(1-2):105-28. PubMed ID: 1597651
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
Fuyama S; Yamamoto H; Fujii Y; Arai S
Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
[TBL] [Abstract][Full Text] [Related]
3. Immunopotentiation in mice bearing a spontaneous transplantable T-cell lymphoma: role of thymic extract.
Shanker A; Singh SM
Neoplasma; 2003; 50(4):272-9. PubMed ID: 12937840
[TBL] [Abstract][Full Text] [Related]
4. Host reactivity against clonable tumor cells and the total tumor cell population, studied in a syngeneic murine lymphoma system.
Gjedde SB
Acta Pathol Microbiol Immunol Scand C; 1983 Apr; 91(2):101-8. PubMed ID: 6349250
[TBL] [Abstract][Full Text] [Related]
5. Acceleration of age-associated immune decline and mortality by early repeated administration of bestatin to C57BL/6 mice.
Bruley-Rosset M; Payelle B; Rappaport H
J Biol Response Mod; 1986 Apr; 5(2):176-90. PubMed ID: 3488372
[TBL] [Abstract][Full Text] [Related]
6. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
7. The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor.
Nagarkatti M; Kaplan AM
J Immunol; 1985 Aug; 135(2):1510-7. PubMed ID: 3159794
[TBL] [Abstract][Full Text] [Related]
8. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells.
Horiguchi S; Petersson M; Nakazawa T; Kanda M; Zea AH; Ochoa AC; Kiessling R
Cancer Res; 1999 Jun; 59(12):2950-6. PubMed ID: 10383160
[TBL] [Abstract][Full Text] [Related]
9. Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's lymphoma ascites tumor in mice.
Ajith TA; Harikumar KB; Thasna H; Sabu MC; Babitha NV
Clin Chim Acta; 2006 Apr; 366(1-2):322-8. PubMed ID: 16380106
[TBL] [Abstract][Full Text] [Related]
10. Role of natural killer cells and macrophages in the nonspecific resistance to tumors in mice stimulated with SMANCS, a polymer-conjugated derivative of neocarzinostatin.
Suzuki F; Pollard RB; Uchimura S; Munakata T; Maeda H
Cancer Res; 1990 Jul; 50(13):3897-904. PubMed ID: 2141295
[TBL] [Abstract][Full Text] [Related]
11. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection.
Tsung K; Dolan JP; Tsung YL; Norton JA
Cancer Res; 2002 Sep; 62(17):5069-75. PubMed ID: 12208763
[TBL] [Abstract][Full Text] [Related]
12. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
Knisely TL; Luckenbach MW; Fischer BJ; Niederkorn JY
J Immunol; 1987 Jun; 138(12):4515-23. PubMed ID: 3108394
[TBL] [Abstract][Full Text] [Related]
13. NK cells from mammary tumor bearing mice do not exert natural killer activity but function as antibody dependent cellular cytotoxicity effectors.
Rivera LM; Lopez DM
Anticancer Res; 1993; 13(1):177-84. PubMed ID: 8476211
[TBL] [Abstract][Full Text] [Related]
14. Modification of host antitumor defense mechanisms in mice by progressively growing tumor.
Maccubbin DL; Mace KF; Ehrke MJ; Mihich E
Cancer Res; 1989 Aug; 49(15):4216-24. PubMed ID: 2525950
[TBL] [Abstract][Full Text] [Related]
15. Effects of native and heat-denatured Abrus agglutinin on tumor-associated macrophages in Dalton's lymphoma mice.
Ghosh D; Maiti TK
Immunobiology; 2007; 212(8):667-73. PubMed ID: 17869644
[TBL] [Abstract][Full Text] [Related]
16. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
17. Effect of allogenic Dalton's lymphoma cells on the activation of murine peritoneal macrophages to tumoricidal state by cisplatin and lipopolysaccharide (LPS).
Singh SM; Singh RK; Sodhi A
Neoplasma; 1992; 39(3):151-5. PubMed ID: 1528319
[TBL] [Abstract][Full Text] [Related]
18. T cell-mediated immunity to oncornavirus-induced tumors. III. Specific and nonspecific suppression in tumor-bearing mice.
Plater C; Debré P; Leclerc JC
Eur J Immunol; 1981 Jan; 11(1):39-44. PubMed ID: 6452278
[TBL] [Abstract][Full Text] [Related]
19. Differential induction of suppressor macrophages by cloned Lewis lung carcinoma variants in mice.
Young MR; Newby M
J Natl Cancer Inst; 1986 Dec; 77(6):1255-60. PubMed ID: 3491925
[TBL] [Abstract][Full Text] [Related]
20. Chemo-immunotherapeutical studies on Dalton's lymphoma in mice using cisplatin and ascorbic acid: synergistic antitumor effect in vivo and in vitro.
Sarna S; Bhola RK
Arch Immunol Ther Exp (Warsz); 1993; 41(5-6):327-33. PubMed ID: 8010874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
